DBI 2013

Drug Profile

DBI 2013

Alternative Names: anti-CD28 antibody; DI 2013; fully human monoclonal antibody - Diabetogen

Latest Information Update: 23 Feb 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abgenix; Diabetogen Biosciences
  • Developer Diabetogen Biosciences
  • Class Monoclonal antibodies
  • Mechanism of Action CD28 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 14 Jan 2003 DBI 2013 is available for licensing [www.diabetogen.com]
  • 04 Dec 2001 Preclinical development for Type-1 diabetes mellitus in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top